Form 4: Bank of America Exits 10% Stake in Aptevo Therapeutics

Bank of America entities report their beneficial ownership in Aptevo Therapeutics has fallen below 10%, ending Section 16 reporting obligations.

Summary

• Bank of America Corporation, Bank of America N.A., and BofA Securities, Inc. (collectively, 'Bank of America entities') are the reporting persons.
• The Bank of America entities are no longer subject to Section 16 of the Securities Exchange Act of 1934.
• This change is due to their beneficial ownership in Aptevo Therapeutics Inc. decreasing below the 10% threshold.
• The earliest transaction date related to this change in beneficial ownership was October 1, 2025.
• The filing was jointly submitted by the Bank of America entities, with Andres Ortiz signing as the Authorized Signatory for each.

Sentiment

Score: 3

Explanation: The reduction of a significant institutional stake by Bank of America entities below 10% is generally a negative signal for the issuer, Aptevo Therapeutics, as it suggests a lack of conviction or a strategic exit by a major investor. While it reduces reporting burden for BoA, it's a negative for APVO.

Positives

• For Bank of America entities: Reduced regulatory reporting burden for their holdings in Aptevo Therapeutics Inc. as they are no longer considered statutory insiders.

Negatives

• For Aptevo Therapeutics Inc.: A significant institutional investor (Bank of America entities) has reduced its stake below 10%, which could be perceived negatively by the market, potentially signaling a lack of conviction or a strategic portfolio adjustment.

Risks

• Potential negative market perception for Aptevo Therapeutics Inc. due to a major institutional investor reducing its stake.
• Increased selling pressure on Aptevo Therapeutics Inc. shares if the disposition of shares by Bank of America entities was recent and substantial.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from Aptevo Therapeutics Inc. or the reporting entities regarding future performance or strategy.

Management Comments

• "This statement is jointly filed by Bank of America Corporation ('Bank of America'), Bank of America N.A. ('BANA'), and BofA Securities, Inc. ('BOFAS'). Bank of America, BANA and BOFAS are submitting this form to indicate they are no longer subject to Section 16 as their beneficial ownership has decreased below 10 percent."

Industry Context

The reduction of a significant institutional stake by Bank of America entities in Aptevo Therapeutics Inc. is a common occurrence in the financial industry, often reflecting portfolio rebalancing, strategic shifts, or changes in investment theses. Such moves can influence market sentiment, particularly for smaller-cap companies like Aptevo, as institutional ownership changes are closely watched.

Stakeholder Impact

• Shareholders: May react negatively to the news of a major institutional investor reducing its stake, potentially leading to downward pressure on the stock price.
• Aptevo Therapeutics Management: May need to address investor concerns regarding the reduction in institutional ownership.

Next Steps

• Aptevo Therapeutics Inc. investors will monitor future institutional ownership reports (e.g., 13F filings) to see if other major investors are also adjusting their positions.
• Bank of America entities will no longer file Section 16 reports for Aptevo Therapeutics Inc. unless their ownership again crosses the 10% threshold.

Key Dates

Recommendation

The reduction of beneficial ownership by Bank of America entities below the 10% threshold, indicating a significant disposition of shares, is a strong negative signal. Large institutional exits often precede or coincide with periods of underperformance for the underlying stock, suggesting that a sophisticated investor has lost conviction or found better opportunities elsewhere. This could lead to increased selling pressure and negative market sentiment for Aptevo Therapeutics Inc.

Keywords

Aptevo Therapeutics, APVO, Bank of America, BAC, Beneficial Ownership, SEC Form 4, Institutional Investor, Stake Reduction, Section 16